Street Calls of the Week

Wall Street analysts issued several significant upgrades this week, with Wells Fargo upgrading CoreWeave (CRWV) to Overweight on its AI infrastructure dominance and NVIDIA's capacity agreement, and Rosenblatt upgrading Ciena (CIEN) to Buy for its pivotal role in interconnecting AI data center clusters. UBS also elevated General Motors (GM) to Buy, projecting higher EPS and margin targets, while BMO upgraded Sarepta (SRPT) to Outperform due to accelerating drug uptake. Seaport Global initiated Frontier Airlines (ULCC) at Neutral, citing competitive uncertainties.

Analysis

This week's analyst actions highlight several distinct, catalyst-driven investment theses, predominantly bullish and centered on artificial intelligence, contrarian value, and event-driven biotech. In the AI infrastructure space, CoreWeave (CRWV) received an Overweight upgrade from Wells Fargo with a $170 price target, based on its dominant position in a GPU-constrained market. The firm's analysis points to superior unit economics, with variable margins per GPU projected to jump from 7% to 28%, and a significant de-risking factor in NVIDIA's commitment to purchase unused capacity through 2032. Similarly, Ciena (CIEN) was upgraded to Buy by Rosenblatt with a $175 price target, driven by a confirmed, high-value (~$200 million) deal with a hyperscaler to interconnect massive AI data centers using its WaveLogic 6 Nano 800G pluggables, a technology that drastically reduces space and power requirements. Outside of tech, General Motors (GM) was upgraded to Buy by UBS, which projects 2026/27 EPS 35-42% above consensus and sees a clear path to GMNA margins of 8-10%. The bank's thesis rests on a strong FCF profile, a ~14% 2025 FCF yield, and the market underappreciating GM's earnings power. In biotech, BMO upgraded Sarepta Therapeutics (SRPT) to Outperform, arguing the market has overly priced in the risk of a negative clinical event for its drug Elevidys, while proprietary channel checks indicate accelerating uptake and potential for sales to surprise in late 2025. In contrast, Seaport Global's Neutral initiation on Frontier Airlines (ULCC) underscores significant uncertainty, with the airline's fate heavily tied to the outcome of competitor Spirit's financial distress, overshadowing its own strategic initiatives.

Key Decisions for Investors

• Investors bullish on the AI hardware build-out should evaluate both CoreWeave for its direct exposure to GPU compute demand, reinforced by favorable unit economics and an NVIDIA backstop, and Ciena for its critical role in high-margin data center interconnectivity.
• For value-oriented investors, General Motors presents a contrarian opportunity, as its current valuation may not reflect the potential for above-consensus earnings and margin expansion outlined by UBS, supported by a robust free cash flow yield and aggressive share buybacks.
• Sarepta Therapeutics represents a high-risk, high-reward biotech play where investors should weigh the potential for significant upside from accelerating Elevidys sales against the severe downside risk of a single negative clinical event, which BMO suggests is currently overpriced by the market.
• It is prudent to exercise caution with Frontier Airlines, as its stock performance is highly dependent on external competitive dynamics, specifically Spirit's potential liquidation or restructuring, which creates a wide range of outcomes and significant uncertainty.